July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

July 02, 2025

Medical Oddities: Leprosy’s Old New World Secret

This week’s clinical grab bag: tea for gloom, ancient leprosy, smoggy fibrosis & power peeing.

Conexiant

July 01, 2025

Five Gynecologic Conditions Linked with Bladder Pain

A new international consensus identifies five gynecologic conditions commonly linked with interstitial cystitis/bladder pain syndrome, urging clinicians to adopt a multidisciplinary and trauma-informed approach to care.

Conexiant

June 27, 2025

Could Age Predict DVT in Cellulitis?

A 10-year study found that individuals aged 70 and above with lower limb cellulitis had significantly higher odds of developing deep vein thrombosis.

Conexiant

June 27, 2025

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant

June 24, 2025

HSV-1 Restructures Human Genome via Hijacking

Researchers uncovered how herpes simplex virus type 1 reprograms human chromatin structure by hijacking transcriptional machinery, potentially revealing a new antiviral target.

Conexiant

June 24, 2025

Shorter Antibiotic Courses: Safe for DFO?

A new meta-analysis aims to clarify optimal antibiotic duration for diabetic foot osteomyelitis

Conexiant

June 24, 2025

Best Fluid for Sepsis? Crystalloids Lead

A network meta-analysis of 32 randomized trials found that balanced crystalloid solutions were associated with lower mortality, reduced acute kidney injury, and shorter hospital stays in patients with sepsis or septic shock.

Conexiant

June 23, 2025

Fidaxomicin Effective, Well-Tolerated in Pediatric CDI

A multicenter study of pediatric patients treated with fidaxomicin for C difficile found over half were cured by two weeks, and only one in five had a recurrence within two months.

Conexiant